Antileishmanial effects of Sargassum vulgare products and prediction of trypanothione reductase inhibition by fucosterol
Aim: To investigate the antileishmanial potency of Sargassum vulgare C. Agardh-derived products and the in silico inhibition of trypanothione reductase by fucosterol. Materials & methods: Sargassum vulgare crude extract and its derived fractions, subfractions and fucosterol were screened against...
Ausführliche Beschreibung
Autor*in: |
Lauve Rachel Tchokouaha Yamthe [verfasserIn] Trudy Janice Philips [verfasserIn] Dorcas Osei-Safo [verfasserIn] Paul Toukam Djouonzo [verfasserIn] Odame Agyapong [verfasserIn] Eunice Dotse [verfasserIn] Patrick Valere Tsouh Fokou [verfasserIn] Samuel Kojo Kwofie [verfasserIn] Fabrice Fekam Boyom [verfasserIn] Alexander Kwadwo Nyarko [verfasserIn] Regina Appiah-Opong [verfasserIn] Michael David Wilson [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2020 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Future Drug Discovery - Future Science Ltd, 2021, 2(2020), 3 |
---|---|
Übergeordnetes Werk: |
volume:2 ; year:2020 ; number:3 |
Links: |
---|
DOI / URN: |
10.4155/fdd-2020-0002 |
---|
Katalog-ID: |
DOAJ010639667 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ010639667 | ||
003 | DE-627 | ||
005 | 20230310030810.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.4155/fdd-2020-0002 |2 doi | |
035 | |a (DE-627)DOAJ010639667 | ||
035 | |a (DE-599)DOAJc6515c78f5194194897dc0679e59be9c | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RS1-441 | |
100 | 0 | |a Lauve Rachel Tchokouaha Yamthe |e verfasserin |4 aut | |
245 | 1 | 0 | |a Antileishmanial effects of Sargassum vulgare products and prediction of trypanothione reductase inhibition by fucosterol |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Aim: To investigate the antileishmanial potency of Sargassum vulgare C. Agardh-derived products and the in silico inhibition of trypanothione reductase by fucosterol. Materials & methods: Sargassum vulgare crude extract and its derived fractions, subfractions and fucosterol were screened against Leishmania major and Leishmania donovani using the MTS and trypanothione reductase colorimetric assays. Macrophages viability was evaluated using the resazurin assay. The inhibition of trypanothione reductase by fucosterol was predicted in silico. Results: The crude extract, fractions 2, 4 and 7, subfractions 8.2 and 8.3 and fucosterol-exhibited antileishmanial activity on promastigote (IC50 = 18.99–156.02 μg/ml), while fraction 1, subfraction 8.2 and fucosterol were active on L. major and L. donovani amastigote (IC50 = 18.47–65.34 μg/ml) with low cytotoxicity. Interestingly, fucosterol showed the best activity against both parasites (IC50 = 18.47–58.21 μg/ml). Strong binding affinities were recorded between fucosterol and Leishmania spp. trypanothione reductases. Conclusion: Fucosterol, which was abundant in S. vulgare, might be responsible for the antileishmanial activity. | ||
650 | 4 | |a antileishmanial activity | |
650 | 4 | |a fucosterol | |
650 | 4 | |a in silico mechanism of binding | |
650 | 4 | |a Sargassum vulgare | |
650 | 4 | |a trypanothione reductase | |
653 | 0 | |a Pharmacy and materia medica | |
700 | 0 | |a Trudy Janice Philips |e verfasserin |4 aut | |
700 | 0 | |a Dorcas Osei-Safo |e verfasserin |4 aut | |
700 | 0 | |a Paul Toukam Djouonzo |e verfasserin |4 aut | |
700 | 0 | |a Odame Agyapong |e verfasserin |4 aut | |
700 | 0 | |a Eunice Dotse |e verfasserin |4 aut | |
700 | 0 | |a Patrick Valere Tsouh Fokou |e verfasserin |4 aut | |
700 | 0 | |a Samuel Kojo Kwofie |e verfasserin |4 aut | |
700 | 0 | |a Fabrice Fekam Boyom |e verfasserin |4 aut | |
700 | 0 | |a Alexander Kwadwo Nyarko |e verfasserin |4 aut | |
700 | 0 | |a Regina Appiah-Opong |e verfasserin |4 aut | |
700 | 0 | |a Michael David Wilson |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Future Drug Discovery |d Future Science Ltd, 2021 |g 2(2020), 3 |w (DE-627)1760793973 |x 26313316 |7 nnns |
773 | 1 | 8 | |g volume:2 |g year:2020 |g number:3 |
856 | 4 | 0 | |u https://doi.org/10.4155/fdd-2020-0002 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/c6515c78f5194194897dc0679e59be9c |z kostenfrei |
856 | 4 | 0 | |u https://www.future-science.com/doi/10.4155/fdd-2020-0002 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2631-3316 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_70 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 2 |j 2020 |e 3 |
author_variant |
l r t y lrty t j p tjp d o s dos p t d ptd o a oa e d ed p v t f pvtf s k k skk f f b ffb a k n akn r a o rao m d w mdw |
---|---|
matchkey_str |
article:26313316:2020----::niesmnaefcsfagsuvlaerdcsnpeitootyaohoee |
hierarchy_sort_str |
2020 |
callnumber-subject-code |
RS |
publishDate |
2020 |
allfields |
10.4155/fdd-2020-0002 doi (DE-627)DOAJ010639667 (DE-599)DOAJc6515c78f5194194897dc0679e59be9c DE-627 ger DE-627 rakwb eng RS1-441 Lauve Rachel Tchokouaha Yamthe verfasserin aut Antileishmanial effects of Sargassum vulgare products and prediction of trypanothione reductase inhibition by fucosterol 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim: To investigate the antileishmanial potency of Sargassum vulgare C. Agardh-derived products and the in silico inhibition of trypanothione reductase by fucosterol. Materials & methods: Sargassum vulgare crude extract and its derived fractions, subfractions and fucosterol were screened against Leishmania major and Leishmania donovani using the MTS and trypanothione reductase colorimetric assays. Macrophages viability was evaluated using the resazurin assay. The inhibition of trypanothione reductase by fucosterol was predicted in silico. Results: The crude extract, fractions 2, 4 and 7, subfractions 8.2 and 8.3 and fucosterol-exhibited antileishmanial activity on promastigote (IC50 = 18.99–156.02 μg/ml), while fraction 1, subfraction 8.2 and fucosterol were active on L. major and L. donovani amastigote (IC50 = 18.47–65.34 μg/ml) with low cytotoxicity. Interestingly, fucosterol showed the best activity against both parasites (IC50 = 18.47–58.21 μg/ml). Strong binding affinities were recorded between fucosterol and Leishmania spp. trypanothione reductases. Conclusion: Fucosterol, which was abundant in S. vulgare, might be responsible for the antileishmanial activity. antileishmanial activity fucosterol in silico mechanism of binding Sargassum vulgare trypanothione reductase Pharmacy and materia medica Trudy Janice Philips verfasserin aut Dorcas Osei-Safo verfasserin aut Paul Toukam Djouonzo verfasserin aut Odame Agyapong verfasserin aut Eunice Dotse verfasserin aut Patrick Valere Tsouh Fokou verfasserin aut Samuel Kojo Kwofie verfasserin aut Fabrice Fekam Boyom verfasserin aut Alexander Kwadwo Nyarko verfasserin aut Regina Appiah-Opong verfasserin aut Michael David Wilson verfasserin aut In Future Drug Discovery Future Science Ltd, 2021 2(2020), 3 (DE-627)1760793973 26313316 nnns volume:2 year:2020 number:3 https://doi.org/10.4155/fdd-2020-0002 kostenfrei https://doaj.org/article/c6515c78f5194194897dc0679e59be9c kostenfrei https://www.future-science.com/doi/10.4155/fdd-2020-0002 kostenfrei https://doaj.org/toc/2631-3316 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2020 3 |
spelling |
10.4155/fdd-2020-0002 doi (DE-627)DOAJ010639667 (DE-599)DOAJc6515c78f5194194897dc0679e59be9c DE-627 ger DE-627 rakwb eng RS1-441 Lauve Rachel Tchokouaha Yamthe verfasserin aut Antileishmanial effects of Sargassum vulgare products and prediction of trypanothione reductase inhibition by fucosterol 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim: To investigate the antileishmanial potency of Sargassum vulgare C. Agardh-derived products and the in silico inhibition of trypanothione reductase by fucosterol. Materials & methods: Sargassum vulgare crude extract and its derived fractions, subfractions and fucosterol were screened against Leishmania major and Leishmania donovani using the MTS and trypanothione reductase colorimetric assays. Macrophages viability was evaluated using the resazurin assay. The inhibition of trypanothione reductase by fucosterol was predicted in silico. Results: The crude extract, fractions 2, 4 and 7, subfractions 8.2 and 8.3 and fucosterol-exhibited antileishmanial activity on promastigote (IC50 = 18.99–156.02 μg/ml), while fraction 1, subfraction 8.2 and fucosterol were active on L. major and L. donovani amastigote (IC50 = 18.47–65.34 μg/ml) with low cytotoxicity. Interestingly, fucosterol showed the best activity against both parasites (IC50 = 18.47–58.21 μg/ml). Strong binding affinities were recorded between fucosterol and Leishmania spp. trypanothione reductases. Conclusion: Fucosterol, which was abundant in S. vulgare, might be responsible for the antileishmanial activity. antileishmanial activity fucosterol in silico mechanism of binding Sargassum vulgare trypanothione reductase Pharmacy and materia medica Trudy Janice Philips verfasserin aut Dorcas Osei-Safo verfasserin aut Paul Toukam Djouonzo verfasserin aut Odame Agyapong verfasserin aut Eunice Dotse verfasserin aut Patrick Valere Tsouh Fokou verfasserin aut Samuel Kojo Kwofie verfasserin aut Fabrice Fekam Boyom verfasserin aut Alexander Kwadwo Nyarko verfasserin aut Regina Appiah-Opong verfasserin aut Michael David Wilson verfasserin aut In Future Drug Discovery Future Science Ltd, 2021 2(2020), 3 (DE-627)1760793973 26313316 nnns volume:2 year:2020 number:3 https://doi.org/10.4155/fdd-2020-0002 kostenfrei https://doaj.org/article/c6515c78f5194194897dc0679e59be9c kostenfrei https://www.future-science.com/doi/10.4155/fdd-2020-0002 kostenfrei https://doaj.org/toc/2631-3316 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2020 3 |
allfields_unstemmed |
10.4155/fdd-2020-0002 doi (DE-627)DOAJ010639667 (DE-599)DOAJc6515c78f5194194897dc0679e59be9c DE-627 ger DE-627 rakwb eng RS1-441 Lauve Rachel Tchokouaha Yamthe verfasserin aut Antileishmanial effects of Sargassum vulgare products and prediction of trypanothione reductase inhibition by fucosterol 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim: To investigate the antileishmanial potency of Sargassum vulgare C. Agardh-derived products and the in silico inhibition of trypanothione reductase by fucosterol. Materials & methods: Sargassum vulgare crude extract and its derived fractions, subfractions and fucosterol were screened against Leishmania major and Leishmania donovani using the MTS and trypanothione reductase colorimetric assays. Macrophages viability was evaluated using the resazurin assay. The inhibition of trypanothione reductase by fucosterol was predicted in silico. Results: The crude extract, fractions 2, 4 and 7, subfractions 8.2 and 8.3 and fucosterol-exhibited antileishmanial activity on promastigote (IC50 = 18.99–156.02 μg/ml), while fraction 1, subfraction 8.2 and fucosterol were active on L. major and L. donovani amastigote (IC50 = 18.47–65.34 μg/ml) with low cytotoxicity. Interestingly, fucosterol showed the best activity against both parasites (IC50 = 18.47–58.21 μg/ml). Strong binding affinities were recorded between fucosterol and Leishmania spp. trypanothione reductases. Conclusion: Fucosterol, which was abundant in S. vulgare, might be responsible for the antileishmanial activity. antileishmanial activity fucosterol in silico mechanism of binding Sargassum vulgare trypanothione reductase Pharmacy and materia medica Trudy Janice Philips verfasserin aut Dorcas Osei-Safo verfasserin aut Paul Toukam Djouonzo verfasserin aut Odame Agyapong verfasserin aut Eunice Dotse verfasserin aut Patrick Valere Tsouh Fokou verfasserin aut Samuel Kojo Kwofie verfasserin aut Fabrice Fekam Boyom verfasserin aut Alexander Kwadwo Nyarko verfasserin aut Regina Appiah-Opong verfasserin aut Michael David Wilson verfasserin aut In Future Drug Discovery Future Science Ltd, 2021 2(2020), 3 (DE-627)1760793973 26313316 nnns volume:2 year:2020 number:3 https://doi.org/10.4155/fdd-2020-0002 kostenfrei https://doaj.org/article/c6515c78f5194194897dc0679e59be9c kostenfrei https://www.future-science.com/doi/10.4155/fdd-2020-0002 kostenfrei https://doaj.org/toc/2631-3316 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2020 3 |
allfieldsGer |
10.4155/fdd-2020-0002 doi (DE-627)DOAJ010639667 (DE-599)DOAJc6515c78f5194194897dc0679e59be9c DE-627 ger DE-627 rakwb eng RS1-441 Lauve Rachel Tchokouaha Yamthe verfasserin aut Antileishmanial effects of Sargassum vulgare products and prediction of trypanothione reductase inhibition by fucosterol 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim: To investigate the antileishmanial potency of Sargassum vulgare C. Agardh-derived products and the in silico inhibition of trypanothione reductase by fucosterol. Materials & methods: Sargassum vulgare crude extract and its derived fractions, subfractions and fucosterol were screened against Leishmania major and Leishmania donovani using the MTS and trypanothione reductase colorimetric assays. Macrophages viability was evaluated using the resazurin assay. The inhibition of trypanothione reductase by fucosterol was predicted in silico. Results: The crude extract, fractions 2, 4 and 7, subfractions 8.2 and 8.3 and fucosterol-exhibited antileishmanial activity on promastigote (IC50 = 18.99–156.02 μg/ml), while fraction 1, subfraction 8.2 and fucosterol were active on L. major and L. donovani amastigote (IC50 = 18.47–65.34 μg/ml) with low cytotoxicity. Interestingly, fucosterol showed the best activity against both parasites (IC50 = 18.47–58.21 μg/ml). Strong binding affinities were recorded between fucosterol and Leishmania spp. trypanothione reductases. Conclusion: Fucosterol, which was abundant in S. vulgare, might be responsible for the antileishmanial activity. antileishmanial activity fucosterol in silico mechanism of binding Sargassum vulgare trypanothione reductase Pharmacy and materia medica Trudy Janice Philips verfasserin aut Dorcas Osei-Safo verfasserin aut Paul Toukam Djouonzo verfasserin aut Odame Agyapong verfasserin aut Eunice Dotse verfasserin aut Patrick Valere Tsouh Fokou verfasserin aut Samuel Kojo Kwofie verfasserin aut Fabrice Fekam Boyom verfasserin aut Alexander Kwadwo Nyarko verfasserin aut Regina Appiah-Opong verfasserin aut Michael David Wilson verfasserin aut In Future Drug Discovery Future Science Ltd, 2021 2(2020), 3 (DE-627)1760793973 26313316 nnns volume:2 year:2020 number:3 https://doi.org/10.4155/fdd-2020-0002 kostenfrei https://doaj.org/article/c6515c78f5194194897dc0679e59be9c kostenfrei https://www.future-science.com/doi/10.4155/fdd-2020-0002 kostenfrei https://doaj.org/toc/2631-3316 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2020 3 |
allfieldsSound |
10.4155/fdd-2020-0002 doi (DE-627)DOAJ010639667 (DE-599)DOAJc6515c78f5194194897dc0679e59be9c DE-627 ger DE-627 rakwb eng RS1-441 Lauve Rachel Tchokouaha Yamthe verfasserin aut Antileishmanial effects of Sargassum vulgare products and prediction of trypanothione reductase inhibition by fucosterol 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim: To investigate the antileishmanial potency of Sargassum vulgare C. Agardh-derived products and the in silico inhibition of trypanothione reductase by fucosterol. Materials & methods: Sargassum vulgare crude extract and its derived fractions, subfractions and fucosterol were screened against Leishmania major and Leishmania donovani using the MTS and trypanothione reductase colorimetric assays. Macrophages viability was evaluated using the resazurin assay. The inhibition of trypanothione reductase by fucosterol was predicted in silico. Results: The crude extract, fractions 2, 4 and 7, subfractions 8.2 and 8.3 and fucosterol-exhibited antileishmanial activity on promastigote (IC50 = 18.99–156.02 μg/ml), while fraction 1, subfraction 8.2 and fucosterol were active on L. major and L. donovani amastigote (IC50 = 18.47–65.34 μg/ml) with low cytotoxicity. Interestingly, fucosterol showed the best activity against both parasites (IC50 = 18.47–58.21 μg/ml). Strong binding affinities were recorded between fucosterol and Leishmania spp. trypanothione reductases. Conclusion: Fucosterol, which was abundant in S. vulgare, might be responsible for the antileishmanial activity. antileishmanial activity fucosterol in silico mechanism of binding Sargassum vulgare trypanothione reductase Pharmacy and materia medica Trudy Janice Philips verfasserin aut Dorcas Osei-Safo verfasserin aut Paul Toukam Djouonzo verfasserin aut Odame Agyapong verfasserin aut Eunice Dotse verfasserin aut Patrick Valere Tsouh Fokou verfasserin aut Samuel Kojo Kwofie verfasserin aut Fabrice Fekam Boyom verfasserin aut Alexander Kwadwo Nyarko verfasserin aut Regina Appiah-Opong verfasserin aut Michael David Wilson verfasserin aut In Future Drug Discovery Future Science Ltd, 2021 2(2020), 3 (DE-627)1760793973 26313316 nnns volume:2 year:2020 number:3 https://doi.org/10.4155/fdd-2020-0002 kostenfrei https://doaj.org/article/c6515c78f5194194897dc0679e59be9c kostenfrei https://www.future-science.com/doi/10.4155/fdd-2020-0002 kostenfrei https://doaj.org/toc/2631-3316 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2020 3 |
language |
English |
source |
In Future Drug Discovery 2(2020), 3 volume:2 year:2020 number:3 |
sourceStr |
In Future Drug Discovery 2(2020), 3 volume:2 year:2020 number:3 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
antileishmanial activity fucosterol in silico mechanism of binding Sargassum vulgare trypanothione reductase Pharmacy and materia medica |
isfreeaccess_bool |
true |
container_title |
Future Drug Discovery |
authorswithroles_txt_mv |
Lauve Rachel Tchokouaha Yamthe @@aut@@ Trudy Janice Philips @@aut@@ Dorcas Osei-Safo @@aut@@ Paul Toukam Djouonzo @@aut@@ Odame Agyapong @@aut@@ Eunice Dotse @@aut@@ Patrick Valere Tsouh Fokou @@aut@@ Samuel Kojo Kwofie @@aut@@ Fabrice Fekam Boyom @@aut@@ Alexander Kwadwo Nyarko @@aut@@ Regina Appiah-Opong @@aut@@ Michael David Wilson @@aut@@ |
publishDateDaySort_date |
2020-01-01T00:00:00Z |
hierarchy_top_id |
1760793973 |
id |
DOAJ010639667 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ010639667</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230310030810.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.4155/fdd-2020-0002</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ010639667</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJc6515c78f5194194897dc0679e59be9c</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RS1-441</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Lauve Rachel Tchokouaha Yamthe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Antileishmanial effects of Sargassum vulgare products and prediction of trypanothione reductase inhibition by fucosterol</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Aim: To investigate the antileishmanial potency of Sargassum vulgare C. Agardh-derived products and the in silico inhibition of trypanothione reductase by fucosterol. Materials & methods: Sargassum vulgare crude extract and its derived fractions, subfractions and fucosterol were screened against Leishmania major and Leishmania donovani using the MTS and trypanothione reductase colorimetric assays. Macrophages viability was evaluated using the resazurin assay. The inhibition of trypanothione reductase by fucosterol was predicted in silico. Results: The crude extract, fractions 2, 4 and 7, subfractions 8.2 and 8.3 and fucosterol-exhibited antileishmanial activity on promastigote (IC50 = 18.99–156.02 μg/ml), while fraction 1, subfraction 8.2 and fucosterol were active on L. major and L. donovani amastigote (IC50 = 18.47–65.34 μg/ml) with low cytotoxicity. Interestingly, fucosterol showed the best activity against both parasites (IC50 = 18.47–58.21 μg/ml). Strong binding affinities were recorded between fucosterol and Leishmania spp. trypanothione reductases. Conclusion: Fucosterol, which was abundant in S. vulgare, might be responsible for the antileishmanial activity.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">antileishmanial activity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">fucosterol</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">in silico mechanism of binding</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Sargassum vulgare</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">trypanothione reductase</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pharmacy and materia medica</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Trudy Janice Philips</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Dorcas Osei-Safo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paul Toukam Djouonzo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Odame Agyapong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Eunice Dotse</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Patrick Valere Tsouh Fokou</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Samuel Kojo Kwofie</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Fabrice Fekam Boyom</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alexander Kwadwo Nyarko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Regina Appiah-Opong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Michael David Wilson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Future Drug Discovery</subfield><subfield code="d">Future Science Ltd, 2021</subfield><subfield code="g">2(2020), 3</subfield><subfield code="w">(DE-627)1760793973</subfield><subfield code="x">26313316</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:2</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:3</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.4155/fdd-2020-0002</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/c6515c78f5194194897dc0679e59be9c</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.future-science.com/doi/10.4155/fdd-2020-0002</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2631-3316</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">2</subfield><subfield code="j">2020</subfield><subfield code="e">3</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Lauve Rachel Tchokouaha Yamthe |
spellingShingle |
Lauve Rachel Tchokouaha Yamthe misc RS1-441 misc antileishmanial activity misc fucosterol misc in silico mechanism of binding misc Sargassum vulgare misc trypanothione reductase misc Pharmacy and materia medica Antileishmanial effects of Sargassum vulgare products and prediction of trypanothione reductase inhibition by fucosterol |
authorStr |
Lauve Rachel Tchokouaha Yamthe |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)1760793973 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut aut aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
RS1-441 |
illustrated |
Not Illustrated |
issn |
26313316 |
topic_title |
RS1-441 Antileishmanial effects of Sargassum vulgare products and prediction of trypanothione reductase inhibition by fucosterol antileishmanial activity fucosterol in silico mechanism of binding Sargassum vulgare trypanothione reductase |
topic |
misc RS1-441 misc antileishmanial activity misc fucosterol misc in silico mechanism of binding misc Sargassum vulgare misc trypanothione reductase misc Pharmacy and materia medica |
topic_unstemmed |
misc RS1-441 misc antileishmanial activity misc fucosterol misc in silico mechanism of binding misc Sargassum vulgare misc trypanothione reductase misc Pharmacy and materia medica |
topic_browse |
misc RS1-441 misc antileishmanial activity misc fucosterol misc in silico mechanism of binding misc Sargassum vulgare misc trypanothione reductase misc Pharmacy and materia medica |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Future Drug Discovery |
hierarchy_parent_id |
1760793973 |
hierarchy_top_title |
Future Drug Discovery |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)1760793973 |
title |
Antileishmanial effects of Sargassum vulgare products and prediction of trypanothione reductase inhibition by fucosterol |
ctrlnum |
(DE-627)DOAJ010639667 (DE-599)DOAJc6515c78f5194194897dc0679e59be9c |
title_full |
Antileishmanial effects of Sargassum vulgare products and prediction of trypanothione reductase inhibition by fucosterol |
author_sort |
Lauve Rachel Tchokouaha Yamthe |
journal |
Future Drug Discovery |
journalStr |
Future Drug Discovery |
callnumber-first-code |
R |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2020 |
contenttype_str_mv |
txt |
author_browse |
Lauve Rachel Tchokouaha Yamthe Trudy Janice Philips Dorcas Osei-Safo Paul Toukam Djouonzo Odame Agyapong Eunice Dotse Patrick Valere Tsouh Fokou Samuel Kojo Kwofie Fabrice Fekam Boyom Alexander Kwadwo Nyarko Regina Appiah-Opong Michael David Wilson |
container_volume |
2 |
class |
RS1-441 |
format_se |
Elektronische Aufsätze |
author-letter |
Lauve Rachel Tchokouaha Yamthe |
doi_str_mv |
10.4155/fdd-2020-0002 |
author2-role |
verfasserin |
title_sort |
antileishmanial effects of sargassum vulgare products and prediction of trypanothione reductase inhibition by fucosterol |
callnumber |
RS1-441 |
title_auth |
Antileishmanial effects of Sargassum vulgare products and prediction of trypanothione reductase inhibition by fucosterol |
abstract |
Aim: To investigate the antileishmanial potency of Sargassum vulgare C. Agardh-derived products and the in silico inhibition of trypanothione reductase by fucosterol. Materials & methods: Sargassum vulgare crude extract and its derived fractions, subfractions and fucosterol were screened against Leishmania major and Leishmania donovani using the MTS and trypanothione reductase colorimetric assays. Macrophages viability was evaluated using the resazurin assay. The inhibition of trypanothione reductase by fucosterol was predicted in silico. Results: The crude extract, fractions 2, 4 and 7, subfractions 8.2 and 8.3 and fucosterol-exhibited antileishmanial activity on promastigote (IC50 = 18.99–156.02 μg/ml), while fraction 1, subfraction 8.2 and fucosterol were active on L. major and L. donovani amastigote (IC50 = 18.47–65.34 μg/ml) with low cytotoxicity. Interestingly, fucosterol showed the best activity against both parasites (IC50 = 18.47–58.21 μg/ml). Strong binding affinities were recorded between fucosterol and Leishmania spp. trypanothione reductases. Conclusion: Fucosterol, which was abundant in S. vulgare, might be responsible for the antileishmanial activity. |
abstractGer |
Aim: To investigate the antileishmanial potency of Sargassum vulgare C. Agardh-derived products and the in silico inhibition of trypanothione reductase by fucosterol. Materials & methods: Sargassum vulgare crude extract and its derived fractions, subfractions and fucosterol were screened against Leishmania major and Leishmania donovani using the MTS and trypanothione reductase colorimetric assays. Macrophages viability was evaluated using the resazurin assay. The inhibition of trypanothione reductase by fucosterol was predicted in silico. Results: The crude extract, fractions 2, 4 and 7, subfractions 8.2 and 8.3 and fucosterol-exhibited antileishmanial activity on promastigote (IC50 = 18.99–156.02 μg/ml), while fraction 1, subfraction 8.2 and fucosterol were active on L. major and L. donovani amastigote (IC50 = 18.47–65.34 μg/ml) with low cytotoxicity. Interestingly, fucosterol showed the best activity against both parasites (IC50 = 18.47–58.21 μg/ml). Strong binding affinities were recorded between fucosterol and Leishmania spp. trypanothione reductases. Conclusion: Fucosterol, which was abundant in S. vulgare, might be responsible for the antileishmanial activity. |
abstract_unstemmed |
Aim: To investigate the antileishmanial potency of Sargassum vulgare C. Agardh-derived products and the in silico inhibition of trypanothione reductase by fucosterol. Materials & methods: Sargassum vulgare crude extract and its derived fractions, subfractions and fucosterol were screened against Leishmania major and Leishmania donovani using the MTS and trypanothione reductase colorimetric assays. Macrophages viability was evaluated using the resazurin assay. The inhibition of trypanothione reductase by fucosterol was predicted in silico. Results: The crude extract, fractions 2, 4 and 7, subfractions 8.2 and 8.3 and fucosterol-exhibited antileishmanial activity on promastigote (IC50 = 18.99–156.02 μg/ml), while fraction 1, subfraction 8.2 and fucosterol were active on L. major and L. donovani amastigote (IC50 = 18.47–65.34 μg/ml) with low cytotoxicity. Interestingly, fucosterol showed the best activity against both parasites (IC50 = 18.47–58.21 μg/ml). Strong binding affinities were recorded between fucosterol and Leishmania spp. trypanothione reductases. Conclusion: Fucosterol, which was abundant in S. vulgare, might be responsible for the antileishmanial activity. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
3 |
title_short |
Antileishmanial effects of Sargassum vulgare products and prediction of trypanothione reductase inhibition by fucosterol |
url |
https://doi.org/10.4155/fdd-2020-0002 https://doaj.org/article/c6515c78f5194194897dc0679e59be9c https://www.future-science.com/doi/10.4155/fdd-2020-0002 https://doaj.org/toc/2631-3316 |
remote_bool |
true |
author2 |
Trudy Janice Philips Dorcas Osei-Safo Paul Toukam Djouonzo Odame Agyapong Eunice Dotse Patrick Valere Tsouh Fokou Samuel Kojo Kwofie Fabrice Fekam Boyom Alexander Kwadwo Nyarko Regina Appiah-Opong Michael David Wilson |
author2Str |
Trudy Janice Philips Dorcas Osei-Safo Paul Toukam Djouonzo Odame Agyapong Eunice Dotse Patrick Valere Tsouh Fokou Samuel Kojo Kwofie Fabrice Fekam Boyom Alexander Kwadwo Nyarko Regina Appiah-Opong Michael David Wilson |
ppnlink |
1760793973 |
callnumber-subject |
RS - Pharmacy |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.4155/fdd-2020-0002 |
callnumber-a |
RS1-441 |
up_date |
2024-07-03T15:56:35.523Z |
_version_ |
1803573993691676672 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ010639667</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230310030810.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.4155/fdd-2020-0002</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ010639667</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJc6515c78f5194194897dc0679e59be9c</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RS1-441</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Lauve Rachel Tchokouaha Yamthe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Antileishmanial effects of Sargassum vulgare products and prediction of trypanothione reductase inhibition by fucosterol</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Aim: To investigate the antileishmanial potency of Sargassum vulgare C. Agardh-derived products and the in silico inhibition of trypanothione reductase by fucosterol. Materials & methods: Sargassum vulgare crude extract and its derived fractions, subfractions and fucosterol were screened against Leishmania major and Leishmania donovani using the MTS and trypanothione reductase colorimetric assays. Macrophages viability was evaluated using the resazurin assay. The inhibition of trypanothione reductase by fucosterol was predicted in silico. Results: The crude extract, fractions 2, 4 and 7, subfractions 8.2 and 8.3 and fucosterol-exhibited antileishmanial activity on promastigote (IC50 = 18.99–156.02 μg/ml), while fraction 1, subfraction 8.2 and fucosterol were active on L. major and L. donovani amastigote (IC50 = 18.47–65.34 μg/ml) with low cytotoxicity. Interestingly, fucosterol showed the best activity against both parasites (IC50 = 18.47–58.21 μg/ml). Strong binding affinities were recorded between fucosterol and Leishmania spp. trypanothione reductases. Conclusion: Fucosterol, which was abundant in S. vulgare, might be responsible for the antileishmanial activity.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">antileishmanial activity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">fucosterol</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">in silico mechanism of binding</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Sargassum vulgare</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">trypanothione reductase</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pharmacy and materia medica</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Trudy Janice Philips</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Dorcas Osei-Safo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paul Toukam Djouonzo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Odame Agyapong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Eunice Dotse</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Patrick Valere Tsouh Fokou</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Samuel Kojo Kwofie</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Fabrice Fekam Boyom</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alexander Kwadwo Nyarko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Regina Appiah-Opong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Michael David Wilson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Future Drug Discovery</subfield><subfield code="d">Future Science Ltd, 2021</subfield><subfield code="g">2(2020), 3</subfield><subfield code="w">(DE-627)1760793973</subfield><subfield code="x">26313316</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:2</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:3</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.4155/fdd-2020-0002</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/c6515c78f5194194897dc0679e59be9c</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.future-science.com/doi/10.4155/fdd-2020-0002</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2631-3316</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">2</subfield><subfield code="j">2020</subfield><subfield code="e">3</subfield></datafield></record></collection>
|
score |
7.399705 |